Key takeaways
Glyxambi (empagliflozin / linagliptin) and metformin are both medications used to treat Type 2 diabetes. Glyxambi is a combination of two medications: empagliflozin, an SGLT2 inhibitor, and linagliptin, a DPP-4 inhibitor. Metformin, on the other hand, is a biguanide. Glyxambi is taken once daily, while metformin is usually taken two to three times a day. Glyxambi is only available as a brand-name medication, whereas metformin is available in generic form. Common side effects of Glyxambi include urinary tract infections and upper respiratory tract infections, while metformin often causes diarrhea and nausea. Glyxambi can interact with medications like Ozempic, while metformin can interact with insulin and glipizide, potentially causing low blood sugar.
